carbamates and Syndrome, VKH (Vogt Koyanagi Harada) studies

carbamates and Syndrome, VKH (Vogt Koyanagi Harada)

Research Excerpts

Excerpt	Relevance	Reference
" Encorafenib is a new BRAF inhibitor currently being tested in phase 3 clinical trials for advanced or metastatic melanoma as monotherapy or in combination with the MEK-inhibitor binimetinib."	7.88	Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma. ( Anastasopoulou, A; Diamantopoulos, PT; Gogas, H; Papaxoinis, G; Stoungioti, S, 2018)
" Encorafenib is a new BRAF inhibitor currently being tested in phase 3 clinical trials for advanced or metastatic melanoma as monotherapy or in combination with the MEK-inhibitor binimetinib."	3.88	Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma. ( Anastasopoulou, A; Diamantopoulos, PT; Gogas, H; Papaxoinis, G; Stoungioti, S, 2018)

Research

Studies (1)

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

0 (0.00)

29.6817

2010's

1 (100.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Studies

Diamantopoulos, PT

Stoungioti, S

Anastasopoulou, A

Papaxoinis, G

Gogas, H

Other Studies

1 other study available for carbamates and Syndrome, VKH (Vogt Koyanagi Harada)

Article	Year
Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma. Melanoma research, 2018, Volume: 28, Issue:6 Topics: Aged, 80 and over; Benzimidazoles; Carbamates; Female; Humans; Melanoma; Protein Kinase Inhibitors;	2018

Article

Year

Melanoma research, 2018, Volume: 28, Issue:6

Topics: Aged, 80 and over; Benzimidazoles; Carbamates; Female; Humans; Melanoma; Protein Kinase Inhibitors;

2018